

Editorial Board



Hidehiko Nakagawa Editor-in-Chief Graduate School of

Pharmaceutical Sciences, Nagoya City University

The Chemical and Pharmaceutical

Bulletin(Chem. Pharm. Bull.) publishes Reviews, Current Topics, Communications, Regular Articles, and Notes monthly in print and online. Chem. Pharm. Bull. is devoted to the publication of original reports on cutting-edge research including creative approaches and novel ideas for sharing the urgent and valuable results with all readers of this journal. Chem. Pharm. Bull. covers various topics of current interest in all of chemistry and interfacing areas of pharmaceutical sciences. The main targeted subjects of Chem. Pharm. Bull. are as follows: Organic Chemistry, Medicinal Chemistry, Chemical Biology, In Silico Science, Analytical Chemistry, Physical Chemistry, Inorganic Chemistry, Physical Pharmacy, Pharmaceutical Engineering, Pharmacognosy, and Natural Product Chemistry.



Takashi Uehara Section Editor-in-Chief Faculty of Pharmaceutical Sciences, Okayama University



Yoshihisa Tomioka Section Editor-in-Chief Graduate School of Pharmaceutical Sciences, Tohoku University



Atsushi Matsuzawa Section Editor-in-Chief Graduate School of Pharmaceutical Sciences, Tohoku University

Masahiro Anada Editor Faculty of Pharmacy, Musashino University

Laurie M. H. Chan Editor University of Ottawa, Canada

Norbert A. Dencher Editor Technische Universit?t Darmstadt, Germany

Hitomi Fujishiro Editor Faculty of Pharmaceutical Sciences, Tokushima Bunri University

Hiroshi Hasegawa Editor Faculty of Pharmaceutical Sciences, Kobe Pharmaceutical University



Yasunori Iwao Section Editor-in-Chief School of Pharmaceutical Science, Wakayama Medical University



Shusuke Tada Section Editor-in-Chief School of Pharmaceutical Sciences, Toho University

Tomohiro Asai Editor School of Pharmaceutical Sciences, University of Shizuoka

Brian L. Crabtree Editor Mercer University College of Pharmacy, U.S.A.

Jeroen S. Dickschat Editor University of Bonn, Germany

Ken-ichi Fujita Editor School of Pharmacy, Showa University

Masayori Hagimori Editor Faculty of Pharmaceutical Sciences, Mukogawa Women's University

Toshiyuki Wakimoto Section Editor-in-Chief

Faculty of Phamaceutical Sciences, Hokkaido University



Masatoshi Tomi Section Editor-in-Chief Faculty of Pharmacy, Keio University

Xavier Decleves Editor University of Paris, France

Hideaki Fujii Editor School of Pharmacy, Kitasato University

Zezong Gu Editor University of Missouri School of Medicine, U.S.A.

Mitsuharu Hattori Editor Graduate School of Pharmaceurtical Sciences, Nagoya City University

Nobuaki Higashi

Editor Faculty of Pharmacy, Hoshi University

Katsuhisa Inoue Editor

School of Pharmacy, Tokyo University of Pharmacy and Life Sciences

Tetsuro Ito Editor Department of Pharmacy, Faculty of Pharmacy, Gifu University of Medical Science

Kazunori Kadota Editor

Faculty of Pharmacy, Osaka Medical and Pharmaceutical University

Kazuyoshi Kawazoe Editor School of Pharmacy, Showa University

Kiyoyuki Kitaichi Editor Gifu Pharmaceutical University

Shinji Kosaka Editor Department of Pharmacy, Kagawa University Hospital

Toshiaki Kume Editor Faculty of Pharmaceutical

Sciences, University of Toyama

Nobuhiko Miura Editor Department of Health Science, Yokohama University of Pharmacy

Yuji Morita Editor

Faculty of Pharmaceutical Sciences, Meiji Pharmaceutical University

Kenjirou Higashi Editor Graduate School of Pharmaceutical Sciences, Chiba University

Ryuji Ikeda Editor Department of Pharmacy. University of Miyazaki Hospital

Junko Ishizaki Editor Faculty of Pharmacy, Institute of Medical, Pharmaceutical & Health Science, Kanazawa University

Keiji Izushi Editor Izushi Pharmacy Co., Ltd.

Katsuyuki Kaneda Editor Institute of Medical, Pharmaceutical and Health Sciences Kanazawa University

Hiroaki Kimura Editor School of Pharmaceutical Sciences, Kyushu University of Health

Tatsuki Koike Editor Takeda Pharmaceutical Company Limited

Naoya Kumagai Editor Faculty of Pharmacy, Keio University

Wei Li Editor Faculty of Pharmaceutical Sciences, Toho University

Nobuaki Mizutani Editor College of Pharmacy, Kinjo Gakuin University

Yuichi Muraki Editor Department of Clinical Pharmacoepidemiology, Kyoto Koji Higai Editor Faculty of Pharmaceutical

Sciences, Toho University

Elichi Hinoi Editor Faculty of Pharmaceutical Sciences, Gifu Pharmaceutical University

Takuya Ito Editor Faculty of Pharmacy, Osaka Ohtani University

Takuya Iwamoto Editor Department of Pharmacy, Mie University Hospital

Makoto Kataoka Editor Faculty of Pharmaceutical Sciences, Setsunan University

Kentaro Kawai Editor Faculty of Pharmaceutical Sciences, Setsunan University

Takashi Kitahara Editor Graduate School of Medicine, Yamaguchi University

Akira Kotani Editor School of Pharmacy, Tokyo University of Pharmacy and Life Sciences

Takashi Kuzuhara Editor Faculty of Pharmaceutical Sciences, Tokushima Bunri University

Osamu Morinaga Editor Daiichi University of Pharmacy

Keiichi Motoyama Editor Graduate School of Pharmaceutical Sciences, Kumamoto University Yoshihito Nakatani Editor Faculty of Pharmaceutical Sciences, Teikyo Helsei University

Makiya Nishikawa Editor Faculty of Pharmaceutical Sciences, Tokyo University of Science

Yukihiro Ohno Editor

Osaka Medical and Pharmaceutical University

Yoshiro Saito Editor National Institute of Health Sciences

Kumiko Sakai-Kato Editor School of Pharmacy, Kitasato University

Shigeki Shimba Editor Scoolo of Pharmacy, Nihon University

Michiru D. Sugawa Editor Charit? Universit?tsmedizin Berlin, Germany

Takayoshi Suzuki Editor The Institute of Scientific and Industrial Research, Osaka University

Yoshiyuki Tanabe Editor Faculty of Pharmaceutical Sciences, Yokohama University of Pharmacy

Futoshi Taura Editor Faculty of Pharmaceutical Sciences, University of Toyama

Kenichiro Todoroki Editor School of Pharmaceutical

Pharmaceutical University

Motohiro Nishida Editor Graduate School of Pharmaceutical Sciences, Kyushu University

Yasuko Obata Editor

Faculty of Pharmaceutical Sciences, Hoshi University

Tomofumi Okuno Editor Faculty of Pharmaceutical Sciences, Setsunan University

Nozomi Saito Editor Meiji Pharmaceutical University

Kenji Sakamoto Editor Faculty of Pharma-Sciences, Teikyo University

Tomoya Shiro Editor Drug Research Division, Sumitomo Dainippon Pharma Co., Ltd.

Changquan Calvin Sun Editor University of Minnesota, U.S.A.

Sayo Suzuki Editor Keio University Faculty of Pharmacy

Ryo Suzuki Editor Faculty of Pharma-Science, Teikyo University

Hikaru Tanaka Editor Faculty of Pharmaceutical Sciences, Toho University

Takaki Toda Editor Faculty of Pharmaceutical Sciences, Hokkaido University of Science Kiyofumi Ninomiya Editor Faculty of Pharmacy, Shujitsu University

Kohji Noguchi

Editor Faculty of Pharmaceutical Sciences, Tokyo University of Science

Shinya Oishi Editor Kyoto Pharmaceutical University

Kei-ichi Ozaki Editor Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts

Yasuo Sato Editor Yokohama University of Pharmacy

Chisato Shimanoe Editor Department of Pharmacy, Saga University Hospital

Nobukazu Shitan Editor Faculty of Pharmaceutical Sciences, Kobe Pharmaceutical University

Toyofumi Suzuki Editor School of Pharmacy, Nihon University

Tsutomu Takahashi Editor School of Pharmacy, Tokyo University of Pharmacy and Life Sciences

Hiroyuki Tanaka Editor Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University

Chihiro Tohda Editor Institute of Natural Medicine, Sciences, University of Shizuoka

Takuhiro Uto Editor Faculty of Pharmaceutical Sciences, Nagasaki International University

Wataru Watanabe Editor Graduate School of Health Sciences, Kyushu University of Health and Welfare

Taku Yamaguchi Editor

Faculty of Pharmaceutical Sciences, Nagasaki International University

Junpei Yamanaka Editor Faculty of Pharmaceutical Sciences, Nagoya City University

Leslie Z. Benet Advisor University of California, U.S.A.

Mukund P. Sibi Advisor North Dakota State University, U.S.A.

Masafumi Ueda Editor Faculty of Pharmaceutical Sciences, Kobe Pharmaceutical University

Tirayut Vilaivan Editor Chulalongkom University, Thailand

Ken-ichi Yamada Editor Institute of Biomedical Sciences, Tokushima University

Katsuhiko Yamamoto Editor Takeda Pharmaceutical Co., Ltd.

Yoshiki Yanagawa Editor School of Pharmaceutical Sciences, Health Sciences University of Hokkaido

Henri B. Kagan Advisor University Paris-Sud, France

Amos B. Smith, III Advisor University of Pennsylvania, U.S.A.

University of Toyama

Naoki Utoguchi Editor Showa Pharmaceutical University

Kahon Wada Editor Faculty of Pharmaceutical Sciences, Doshisha Women's College

Shinji Yamaguchi Editor Faculty of Pharmaceutical Sciences, Telkyo University

Yoshihisa Yamamoto Editor Faculty of Pharmaceutical Sciences, Teikyo Heisel University

Yasuo Yoshioka Editor

Institute for Open and Transdisciplinary Research Initiatives, Osaka University

Manfred Schubert-Zsilavecz Advisor Johann Wolfgang Goethe University, Germany

Subject Area

Physics Chemistry Biology, Life Sciences and Basic Medicine Agriculture and Food Sciences Pharmaceutical Sciences Environmental Sciences

Other relevant information

Title Chemical and Pharmaceutical Bulletin

Publisher

The Pharmaceutical Society of Japan

Address

2-12-15, Shibuya, Shibuya-ku, Tokyo 150-0002, Japan

Contact email address

(Please change "(at)" into "@".) ronb(at)pharm.or.jp

URL

https://www.pharm.or.jp/eng/

Chemical and Pharmaceutical Bulletin

Online ISSN : 1347-5223 Print ISSN : 0009-2363 ISSN-L : 0009-2363

Journal home Advance online publication Featured articles About the journal

Volume 60, Issue 2

Showing 1-20 articles out of 20 articles from the selected issue

Communication to the Editor

Three-Dimensional Solution Structure of Bottromycin A₂: A Potent Antibiotic Active against Methicillin-Resistant *Staphylococcus aureus* and Vancomycin-Resistant *Enterococci*

Hiroaki Gouda, Yutaka Kobayashi, Takeshi Yamada, Tetsuya Ideguchi, Aki ...

Type: Communication to the Editor 2012 Volume 60 Issue 2 Pages 169-171 Published: February 01, 2012 Released: February 01, 2012

DOI https://doi.org/10.1248/cpb.60.169

JOURNALS FREE ACCESS

SUPPLEMENTARY MATERIAL

Show abstract

Download PDF (1386K)

Regular Articles

Development and Evaluation of a Monolithic Floating Drug Delivery System for Acyclovir

Naser Tavakoli, Jaleh Varshosaz, Farid Dorkoosh, Sedigheh Motaghi, Lan ...

Type: Regular Article 2012 Volume 60 Issue 2 Pages 172-177 Published: February 01, 2012 Released: February 01, 2012

DOI https://doi.org/10.1248/cpb.60.172

JOURNALS FREE ACCESS

Constituents from the Roots of *Taraxacum platycarpum* and Their Effect on Proliferation of Human Skin Fibroblasts

Tsutomu Warashina, Kaoru Umehara, Toshio Miyase

Type: Regular Article 2012 Volume 60 Issue 2 Pages 205-212 Published: February 01, 2012 Released: February 01, 2012

DOI https://doi.org/10.1248/cpb.60.205

JOURNALS FREE ACCESS

Show abstract

Download PDF (1157K)

Rupestines F-M, New Guaipyridine Sesquiterpene Alkaloids from Artemisia rupestris

Fei He, Alfarius Eko Nugroho, Chin Piow Wong, Yusuke Hirasawa, Osamu S

Type: Regular Article 2012 Volume 60 Issue 2 Pages 213-218 Published: February 01, 2012 Released: February 01, 2012

DOI https://doi.org/10.1248/cpb.60.213

JOURNALS FREE ACCESS

Show abstract

Download PDF (788K)

New Tricyclic Alkaloids, Cassiarins G, H, J, and K from Leaves of Cassia siamea

Jun Deguchi, Tomoe Hirahara, Yusuke Hirasawa, Wiwied Ekasari, Aty Widy ...

Type: Regular Article 2012 Volume 60 Issue 2 Pages 219-222 Published: February 01, 2012 Released: February 01, 2012

DOI https://doi.org/10.1248/cpb.60.219

JOURNALS FREE ACCESS

Show abstract

Download PDF (580K)

New Tricyclic Alkaloids, Cassiarins G, H, J, and K from Leaves of *Cassia siamea*

Jun Deguchi,^{*a*} Tomoe Hirahara,^{*a*} Yusuke Hirasawa,^{*a*} Wiwied Ekasari,^{*b*} Aty Widyawaruyanti,^{*b*} Osamu Shirota,^{*c*} Motoo Shiro,^{*d*} and Hiroshi Morita^{*,*a*}

^a Faculty of Pharmaceutical Sciences, Hoshi University; 2–4–41 Ebara, Shinagawa, Tokyo 142–8501, Japan: ^b Faculty of Pharmacy, Airlangga University; Jalan Dharmawangsa Dalam, Surabaya 60286, Indonesia: ^c Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University; 1314–1 Shido, Sanuki, Kagawa 769–2193, Japan: and ^d X-Ray Research Laboratory, Rigaku Corporation; Akishima, Tokyo 196–8666, Japan. Received October 24, 2011; accepted November 28, 2011; published online December 5, 2011

Four new alkaloids, cassiarins G, H, J, and K (1—4) which showed moderate antiplasmodial activity against *Plasmodium falciparum* 3D7, were isolated from the leaves of *Cassia siamea* (Leguminosae) and the structures of 1—4 were elucidated by 1D- and 2D-NMR analysis and X-ray crystallographic analysis.

Key words alkaloid; Cassia siamea; cassiarin; antiplasmodial activity; Plasmodium falciparum 3D7

Cassia siamea LAM. (Leguminosae), has been widely used in traditional medicine, particularly for the treatment of periodic fever and malaria in Indonesia.^{1,2)} Cassiarin A,³⁾ an unprecedented tricyclic alkaloid exhibiting potent antimalarial activity against P. falciparum in vitro as well as P. berghei *in vivo*,⁴⁾ was isolated from the leaves of C. *siamea* and has attracted the attention of synthetic organic chemists⁵⁻⁷⁾ as well as pharmacologists.⁸⁾ Recently, we have also reported the synthesis of a series of a hydroxyl and a nitrogen-substituted derivatives of cassiarins A and B and their antimalarial activity against P. falciparum in vitro as well as a vasorelaxation activity.9) Furthermore, we isolated a novel biaryl tetracyclic alkaloid, cassirin F and achieved its total synthesis.¹⁰⁾ In our continuing investigation of the pharmacologically and structurally unique alkaloids from this plant, we have isolated four new alkaloids possessing tricyclic skeleton. We herein report the structure elucidation of these alkaloids and antiplasmodial activity against P. falciparum 3D7.

The crude basic fraction obtained by a conventional procedure from the MeOH extract of the leaves of *C. siamea*, was purified by repeated chromatography to afford new alkaloids, cassiarins G (1; 0.0064%), H (2; 0.00008%), J (3; 0.0022%), and K (4; 0.0012%), along with cassiarins A and $B^{3)}$ and 5-acetonyl-7-hydroxy-2-methylchromone.¹¹

Cassiarin G (1) was obtained as yellowish needles (mp 213—218°C) and showed the molecular formula, $C_{14}H_{13}NO_4$, which was determined by high resolution-electrospray ionization-time-of-flight-mass spectrometry (HR-ESI-TOF-MS) [*m*/*z* 260.0921, (M+H)⁺, -0.2 mmu]. IR absorptions implied the presence of hydroxy and/or amino (3116 cm⁻¹) and carbonyl (1673 cm⁻¹) functionalities. ¹H- and ¹³C-NMR data are presented in Table 1. The ¹³C-NMR spectrum revealed 14 carbon signals due to one carbonyl carbon, six sp^2 and one sp^3 quaternary carbons, three sp^2 methines, and three methyl groups. Among them, four sp^2 quaternary carbons (δ_C 144.0, 152.0, 155.4, 168.9), one sp^3 quaternary carbon (δ_C 106.8), and one sp^3 methyl carbon (δ_C 50.5) were ascribed to those bearing a nitrogen or an oxygen atom.

A partial structure, C-10 to C-12 was deduced from analysis of the ¹H–¹H correlation spectroscopy (COSY) spectrum including a long range coupling from H₂-12 to H-10. The heteronuclear multiple bond connectivity (HMBC) correlations for H-10 of C-4a ($\delta_{\rm C}$ 110.2) and C-5 ($\delta_{\rm C}$ 142.0), H-6 of C-10 $(\delta_{\rm C} 121.7)$, and H-8 of C-4a, C-6 $(\delta_{\rm C} 103.0)$, and C-7 $(\delta_{\rm C} 168.9)$ gave rise to 3-methylisoquinolin-6-ol core, which is the same as the partial structure of cassiarin A. The other partial structure was assigned by HMBC correlations for H₃-9 and H₃-13 of C-2 and H₃-9 of C-3 ($\delta_{\rm C}$ 189.0) and the downfield chemical shifts of C-2 ($\delta_{\rm C}$ 106.8) and C-8a ($\delta_{\rm C}$ 155.4) suggested the presence of an ether linkage between C-2 and C-8a to form a 2-methyl-2-methoxy-3-carbonylpyran ring. Thus, cassiarin G (1) was assigned to be a 2-methoxycassiarin A-3-one (Fig. 1). The proposed structure inferred by spectroscopic analysis was confirmed by X-ray crystallographic analysis (Fig. 2). 1 was found as a racemic form base on X-ray crystallographic information.

Cassiarin H (2) showed the molecular formula, $C_{19}H_{21}NO_6$, which was determined by HR-ESI-TOF-MS [*m*/*z* 360.1441, (M+H)⁺, -0.6 mmu]. IR absorptions implied the presence of carbonyl (1726, 1683 cm⁻¹) functionality. The gross structure of **2** was elucidated by analyses of 2D-NMR data including ¹H-¹H COSY, heteronuclear multiple quantum coherence



Chart 1

Table 1. ¹H-NMR Data [$\delta_{\rm H}$ (*J*, Hz)] and ¹³C-NMR Data [$\delta_{\rm C}$] of Cassiarins G, H, J, and K (1–4) in Methanol- d_4 at 300 K^a)

	1		2		3		4	
Position	$\delta_{ m H}$	$\delta_{ m C}$	$\delta_{ m H}$	$\delta_{ m C}$	$\delta_{ m H}$	$\delta_{ m C}$	$\delta_{ m H}$	$\delta_{ m C}$
2		106.8		102.2		107.1		157.4
3		189.0		187.0		76.1		113.7
4		152.0		137.5		156.9		148.4
4a		110.2		115.9		111.0		112.8
5		142.0		141.4		141.0		139.9
6	6.88 (1H, brs)	103.0	6.33 (1H, d, 1.8)	106.5	6.83 (1H, brs)	103.1	6.57 (1H, brs)	102.5
7		168.9		183.5		167.9		163.0
8	6.79 (1H, brs)	107.6	6.58 (1H, d, 1.8)	116.6	6.74 (1H, brs)	107.3	6.54 (1H, brs)	100.5
8a		155.4		153.2		154.4		155.2
9	1.71 (3H, s)	14.9	1.79 (3H, s)	17.4	1.76 (3H, s)	15.5	2.41 (3H, s)	18.2
10	7.70 (1H, s)	121.7	7.40 (1H, s)	121.8	7.57 (1H, s)	120.3	6.91 (1H, s)	115.3
11		144.0		145.1		141.0		153.8
12	2.73 (3H, s)	19.7	2.72 (3H, s)	20.1	2.65 (3H, s)	20.3	2.45 (3H, s)	23.9
13	3.25 (3H, s)	50.5	3.42 (3H, s)	51.3	3.20 (3H, s)	50.6		
14a			4.40 (2H, t, 8.5)	49.9	2.87 (1H, d, 13.2)	43.6		
14b					3.00 (1H, d, 13.2)			
15a			1.90 (1H, m)	27.0		170.7		
15b			2.14 (1H, m)					
16			2.51 (2H, m)	31.2	3.40 (3H, s)	52.4		
17				174.5				
18			3.69 (3H, s)	52.3				

a) δ in ppm.



Fig. 1. Selected 2D-NMR Correlations for Cassiarin G (1)



Fig. 2. An ORTEP Drawing for Cassiarin G (1)

(HMQC), and HMBC spectra in methanol- d_4 (Fig. 3). The ¹H- and ¹³C-NMR (Table 1) spectra of **2**, which is like a combination of those of cassiarins B and G, indicated that **2** was concluded to be a 2-methoxycassiarin B-3-one. Due to the no optical rotation and Cotton effects, **2** might be racemic form.

Cassiarin J (3) showed the molecular formula, $C_{17}H_{19}NO_6$, which was determined by HR-ESI-TOF-MS [*m*/*z* 332.1107,



Fig. 3. Selected 2D-NMR Correlations for Cassiarin H (2)



Fig. 4. Selected 2D-NMR Correlations for Cassiarin J (3)

 $(M-H)^-$, -2.0 mmu]. IR absorptions implied the presence of hydroxy and/or amino (3370 cm⁻¹) and carbonyl (1632 cm⁻¹) functionalities. ¹H- and ¹³C-NMR spectra are presented in Table 1. The gross structure of **3** was elucidated by analyses of 2D-NMR data including ¹H-¹H COSY, HMQC, and HMBC spectra in methanol- d_4 (Fig. 4). The structure of **3** resembled those of **1** except for the chemical shift and a moiety of C-3 (δ_C 76.1). The presence of a methylacetate and hydroxyl moiety at C-3 was supported by HMBC correlations for H₂-14 of C-2 (δ_C 107.1), C-3, C-4 (δ_C 156.9), and C-15 (δ_C 170.7) and H₃-16 of C-15. Thus, cassiarin J (**3**) was concluded to be methyl 3-hydroxy-2-methoxy-3-cassiarin A-acetate. The relative configuration of **3** was elucidated by rotating frame Overhauser



Fig. 5. Most Stable Conformation of Cassiarin J (3) by Monte Carlo Conformational Search and the Selected ROESY Correlations



Fig. 6. Selected 2D-NMR Correlations for Cassiarin K (4)

enhancement spectroscopy (ROESY) correlations as depicted in the computer-generated three-dimensional drawing (Fig. 5). The ROESY correlations for H_3 -9/ H_3 -13 and H_2 -14 suggested the methyl at C-2 and the hydroxy at C-3 took equatorial orientations as in Fig. 5. The energetically most stable conformation of **3** found in the Monte Carlo conformational search¹²) satisfied with the above-mentioned ROESY correlations. No optical rotation and Cotton effects indicated **3** might be racemic form.

Cassiarin K (4) showed the molecular formula, $C_{13}H_{10}NO_2Cl$, which was determined by HR-ESI-TOF-MS [*m*/*z* 248.0474, (M+H)⁺, -0.4 mmu]. IR absorption implied the presence of hydroxy and/or amino (3420 cm⁻¹) functionality. The gross structure of 4 was elucidated by analyses of 2D-NMR data including ¹H–¹H COSY, HMQC, and HMBC spectra in methanol- d_4 (Fig. 6). The ¹H- and ¹³C-NMR (Table 1) spectra of 4 are similar to those of cassiarin A except for the absence of H-3. The C-3 resonance of 4 was observed as a quaternary carbon at δ 113.7 as expected for a chlorine-bearing carbon resonance. Cassiarin K (4) is the first halogenated cassiarin analogue, has a structure in which H-3 of cassiarin A is substituted by a chlorine atom.

Biogenetically, cassiarins G, H and J (1—3) could be derived through oxidation of 5-acetonyl-7-hydroxy-2-methylchromone.

Cassiarin J (**3**) showed moderate *in vitro* antiplasmodial activity against *P. falciparum* 3D7 (IC₅₀ **3**: 0.3μ M). Whereas cassiarins G, H, and K (IC₅₀ **1**: >50 μ M; **2**: >50 μ M; **4**: 1.4μ M) were less active than cassiarin J (**3**), although they contained the similar cassiarin A-type skeleton.

Experimental

General Experimental Procedures 1D- and 2D-NMR spectra were recorded on a Bruker AV 400, Inova500, and Bruker AVANCE 700 spectrometers and chemical shifts were referenced to the residual solvent peaks ($\delta_{\rm H}$ 3.31 and $\delta_{\rm C}$ 49.0 for methanol- d_4). Standard pulse sequences were employed for

the 2D-NMR experiments. ${}^{1}\text{H}{-}^{1}\text{H}$ COSY and ROESY spectra were measured with spectral widths of both dimensions of 4800 Hz, and 32 scans with two dummy scans were accumulated into 1 K data points for each of 256 t_1 increments. ROESY spectra in the phase sensitive mode were measured with a mixing time of 800 ms. For HMQC spectra in the phase sensitive mode and HMBC spectra, a total of 256 increments of 1 K data points were collected. For HMBC spectra with *Z*-axis PFG, a 50 ms delay time was used for long-range C–H coupling. Zero-filling to 1 K for F_1 and multiplication with squared cosine-bell windows shifted in both dimensions were performed prior to 2D Fourier transformation.

Material Leaves of *C. siamea* were collected at Purwodadi Botanical Garden in 2007. The botanical identification was made by Ms. Sri Wuryanti, Purwodadi Botanical Garden, Indonesia. A voucher specimen has been deposited at Purwodadi Botanical Garden, Pasuruan, Indonesia.

Extraction and Isolation The leaves of *C. siamea* (0.5 kg) were extracted with MeOH, and the extract was partitioned between EtOAc and 3% tartaric acid. The aqueous layer was adjusted at pH 9 with saturated Na₂CO₃ aq. and extracted with CHCl₃. CHCl₃-soluble alkaloidal materials were roughly separated by silica gel column chromatography (CHCl₃/MeOH, $1:0\rightarrow0:1$) to give seven fractions (1—7). The fraction 4 was rechromatogaphed over SiO₂ (CHCl₃/MeOH, $1:0\rightarrow0:1$), ODS (MeOH/H₂O, 40:60 \rightarrow 100:0), and then purified by ODS HPLC (MeOH/0.1% TFA aq, 40:60) to afford cassiarin G (1, 0.0064%), cassiarin H (2, 0.00008%), cassiarin J (3, 0.0022%), and cassiarin K (4, 0.0012%) together with cassiarin A and 5-acetonyl-7-hydroxy-2-methylchromone.

Cassiarin G (1): Yellowish needles (mp 213—218°C) crystal solid; IR (KBr) v_{max} 3116, 2316, and 1673 cm⁻¹; UV (MeOH) λ_{max} 213 (ε 16300), 243 (19600), 269 (10900), and 325 (2100) nm; ¹H- and ¹³C-NMR, see Table 1; ESI-MS *m/z* 260 (M+H)⁺; HR-ESI-TOF-MS *m/z* 260.0921 [(M+H)⁺], (Calcd for C₁₄H₁₄NO₄, 260.0923).

Cassiarin H (2): Yellow amorphous solid; IR (film) v_{max} 1726 and 1683 cm⁻¹; UV (MeOH) λ_{max} 215 (ε 2135), 238 (1978), 312 (1424), 387 (443), and 496 (310) nm; ¹H- and ¹³C-NMR, see Table 1); ESI-MS *m/z* 360 (M+H)⁺; HR-ESI-TOF-MS *m/z* 360.1441 [(M+H)⁺], (Calcd for C₁₉H₂₂NO₆, 360.1447).

Cassiarin J (3): Yellow amorphous solid; IR (film) v_{max} 3370 and 1632 cm⁻¹;UV (MeOH) λ_{max} 242 (ε 16100), 289 (2600), and 327 (sh, 1600) nm;¹H- and ¹³C-NMR, see Table 1); ESI-MS m/z 334 (M+H)⁺; HR-ESI-TOF-MS m/z 332.1127 [(M-H)⁻], (Calcd for C₁₇H₁₈NO₆, 332.1107).

Cassiarin K (4): Yellow amorphous solid; IR (KBr) v_{max} 3420 cm⁻¹; UV (MeOH) λ_{max} 201 (ε sh, 5500), 219 (7300), and 336 (1500) nm; ¹H- and ¹³C-NMR, see Table 1; ESI-MS m/z 248 (M+H)⁺; HR-ESI-TOF-MS m/z 248.0474 [(M+H)⁺], (Calcd for C₁₃H₁₁NO₂Cl, 248.0478).

Antiplasmodial Activity Human malaria parasites were cultured according to the method of Trager and Jensen.¹³⁾ The antimalarial activity of the isolated compounds was determined by the procedure described by Budimulya *et al.*¹⁴⁾ In brief, stock solutions of the samples were prepared in dimethyl sulfoxide (DMSO) (final DMSO concentrations of <0.5%) and were diluted to the required concentration with complete medium (RPMI 1640 supplemented with 10% human plasma, 25 mM N-(2-hydroxyethyl)piperazine-N'-2-ethanesulfonic acid (HEPES) and 25 mM N-HCO₃) until the final concentrations of

samples in culture plate wells were 10; 1; 0.1; 0.01; 0.001 μ g/mL. The malarial parasite *P. falciparum* 3D7 clone was propagated in a 24-well culture plates. Growth of the parasite was monitored by making a blood smear fixed with MeOH and stained with Geimsa stain. The antimalarial activity of each compound was expressed as an IC₅₀ value, defined as the concentration of the compound causing 50% inhibition of parasite growth relative to an untreated control. The percentage of growth inhibition was expressed according to following equation: growth inhibition %=100-[(test parasitaemia/control parasitemia)×100. Chloroqine: IC₅₀ 0.011 μ M.

X-Ray Crystallography Measurement was made on a Rigaku RAXIS RAPID imaging plate area detector with graphite monochromated CuKa radiation. Crystal data of cassiarin G: A yellow, block, triclinic, C₁₄H₁₅NO₅, M=277.28, crystal dimensions 0.12×0.12×0.05 mm, space group P-1 (#2), a=7.22313(13)Å, b=9.79354(18)Å, c=10.3279(7)Å, V=629.94(5)Å³, Z=2, $D_{calc}=1.462$ g/cm³. Of the 21093 reflections that were obtained, 2292 were unique ($R_{int}=0.026$). The structure was solved by direct methods. R1=0.0371 $(I \ge 2.00\sigma(I))$. All calculations were performed using the CrystalStructure crystallographic software package except for refinement, which was performed using SHELXL-97. The refined fractional atomic coordinates, bond lengths, bond angles, and thermal parameters have been deposited at the Cambridge Crystallographic Data Centre (CCDC). CCDC 848465 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via http://www. ccdc.cam.ac.uk/deposit, or from the CCDC, 12 Union Road, Cambridge CB2 1EZ, U.K. (Fax: +44 1223 336 033; e-mail: deposit@ccdc.cam.ac.uk).

Acknowledgment. This work was partly supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and a Grant from the Open Research Center Project. We also acknowledge the financial support provided by Faculty of Pharmacy, Airlangga University for antimalarial activity.

References

- Mbatchi S. F., Mbatchi B., Banzouzi J. T., Bansimba T., Nsonde Ntandou G. F., Ouamba J. M., Berry A., Benoit-Vical F., J. Ethnopharmacol., 104, 168—174 (2006).
- Sanon S., Ollivier E., Azas N., Mahiou V., Gasquet M., Ouattara C. T., Nebie I., Traore A. S., Esposito F., Balansard G., Timon-David P., Fumoux F., *J. Ethnopharmacol.*, **86**, 143–147 (2003).
- Morita H., Oshimi S., Hirasawa Y., Koyama K., Honda T., Ekasari W., Indrayanto G., Zaini N. C., Org. Lett., 9, 3691–3693 (2007).
- Ekasari W., Indrayanto G., Zaini N. C., Syafruddin D., Honda T., Morita H., *Heterocycles*, 78, 1831–1836 (2009).
- Rudyanto M., Tomizawa Y., Morita H., Honda T., Org. Lett., 10, 1921–1922 (2008).
- 6) Yao Y. S., Yao Z. J., J. Org. Chem., 73, 5221-5225 (2008).
- Kanputhorn S., Petsom A., Thamyongkit P., *Tetrahedron*, 66, 7539–7543 (2010).
- Matsumoto T., Kobayashi T., Ishida K., Hirasawa Y., Morita H., Honda T., Kamata K., *Biol. Pharm. Bull.*, 33, 844–848 (2010).
- Morita H., Tomizawa Y., Deguchi J., Ishikawa T., Arai H., Zaima K., Hosoya T., Hirasawa Y., Matsumoto T., Kamata K., Ekasari W., Widyawaruyanti A., Wahyuni T. S., Zaini N. C., Honda T., *Bioorg. Med. Chem.*, **17**, 8234–8240 (2009).
- Deguchi J., Hirahara T., Oshimi S., Hirasawa Y., Ekasari W., Shirota O., Honda T., Morita H., Org. Lett., 13, 4344–4347 (2011).
- Arora S., Deymann H., Tiwri R. D., Winterfeldt E., *Tetrahedron*, 27, 981–984 (1971).
- Mohamadi F., Richards N. G. J., Guida W. C., Liskamp R., Lipton M., Caulfield C., Chang G., Hendrickson T., Still W. C., *J. Comput. Chem.*, 11, 440–467 (1990).
- 13) Trager W., Jensen J. B., Science, 193, 673-675 (1976).
- Budimulya A. S., Syafruddin T. P., Wilariat P., Marzuki S., Mol. Biochem. Parasitol., 84, 137–141 (1997).

Bukti – Subject Area and Category, Quartile dan SJR Tahun Terbit (2012)



Bukti – Scopus Coverage, Publisher dan ISSN

Scopus Preview	Q Author Search	Sources ⑦	 Create account	Sign in						
Source details			Feedback > Com	are sources >						
Chemical and Pharmaceutical Bull Formerly known as: Pharmaceutical bulletin	etin		CiteScore 2021 3.0	0						
Scopus coverage years: from 1958 to Present Publisher: Pharmaceutical Society of Japan ISSN: 0009-2363 E-ISSN: 1347-5223		5JR 2021 0.376	Ū							
Subject area: (Chemistry: General Chemistry) (Pharmacology, Toxicology and Pharmaceutics: Drug Discovery) SNIP 2021 Source type: Journal SNIP 2021 View all documents > Set document alert										
CiteScore CiteScore rank & trend Scopus content coverage										
i Improved CiteScore methodology CiteScore 2021 counts the citations received in 2018-2021 to articles, reviews, conference papers, book chapters and data papers published in 2018-2021, and divides this by the number of publications published in 2018-2021. Learn more >										
CiteScore 2021 3.0 = $\frac{2,002 \text{ Citations } 2018 - 2021}{663 \text{ Documents } 2018 - 2021}$ Calculated on 05 May, 2022	CiteScoreTracker 2022 ① 2.6 = $\frac{1,461 \text{ Citations to date}}{560 \text{ Documents to date}}$ Last updated on 06 June, 2022 · Updated monthly									
CiteScore rank 2021 ①										
Category Rank Percentile	_									
Chemistry General Chemistry #199/409 51s	t									
Pharmacology, Toxicology and Pharmaceutics #97/154 37th Drug Discovery										